Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 4/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.35 |
| ▸ | OXTR | P30559 | 2/20 | 0.35 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.35 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | STS | P08842 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3048701 | 0.94 | MCOLN3 (0.34) | NR1H2ATRATRIPCHEK1MEN1 | |
| SCHEMBL3054403 | 0.92 | NR1H2 (0.36) | NR1H2ATRATRIPOXTRAVPR1B | |
| SCHEMBL3047451 | 0.90 | NR1H2 (0.40) | NR1H2ATRATRIPACHE | |
| SCHEMBL3049966 | 0.90 | ALDH1A1 (0.36) | NR1H2ATRATRIPCHEK1MEN1 | |
| SCHEMBL3047269 | 0.90 | MEN1 (0.37) | NR1H2ATRATRIPCHEK1ACHE | |
| SCHEMBL3054209 | 0.90 | LMNA (0.39) | NR1H2OXTRAVPR1BAVPR1AACHE | |
| SCHEMBL3045896 | 0.90 | MEN1 (0.34) | NR1H2CHEK1ACHEMEN1KMT2A | |
| SCHEMBL3048132 | 0.88 | NR1H2 (0.35) | NR1H2ATRATRIP | |
| SCHEMBL3042102 | 0.88 | LMNA (0.34) | NR1H2OXTRAVPR1BAVPR1AACHE | |
| SCHEMBL3042556 | 0.87 | NR1H2 (0.38) | NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1880993-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054407-A1 | Nitrogen-containing heterocyclic compound | NR4A1, NR5A2, PRMT8 | NR1H2 21/4885ATR 1385/4885ATRIP 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.